Ozempic is what's known as a GLP-1, a drug class that's prescribed to manage Type 2 diabetes and is effective for weight loss ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Hims & Hers achieved 136% YoY subscriber growth and unveiled ambitious 2030 goals. Discover how precision medicine drives ...

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is ...

Dive deeper with STAT+. Gain unlimited access to expert analysis, newsletters, events, and news alerts.

According to recent reporting, Gov. Josh Shapiro is considering cutting off access to the weight loss drugs like Zepbound and Wegovy to all Medicaid recipients in the state who are not dangerously ...

Those projections include the impact of tariffs as of May 1, but since that situation might change, there's some uncertainty. Despite the factors that led to its post-earnings decline, Eli Lilly ...

As Stat reports, the federal judge's ruling means patients will lose access to less-expensive versions of Eli Lilly's weight loss drug, as well as diabetes treatment Mounjaro, from compounding ...